⚠️ Research Use Only. All peptides described on this page are sold by Webber Science strictly for in vitro laboratory and research purposes. They are not intended for human or veterinary use. This content does not constitute medical advice.
Contents
Introduction: Peptides in Longevity Research
Aging is driven by interconnected molecular processes — telomere attrition, mitochondrial dysfunction, cellular senescence, epigenetic drift, and declining immune surveillance — collectively termed the “hallmarks of aging.” Over the past two decades, a subset of short-chain peptides and coenzymes has attracted significant research interest for their ability to modulate specific longevity-relevant pathways in preclinical models.
This guide provides Canadian researchers with a science-first overview of five widely studied longevity and anti-aging peptides: Epithalon (Epitalon), MOTS-c, DSIP, NAD+, and Thymosin Alpha-1. For each compound we review the mechanism of action, key preclinical findings, and the current state of the research literature.
All five compounds are available through Webber Science with certificates of analysis and Canadian shipping.
For deeper reading on individual compounds, explore our dedicated cluster pages: Epithalon Telomere Research, DSIP Research Guide, NAD+ Research Guide, and DSIP Sleep & Cognitive Research. For information on combining these compounds, see our Nootropic Peptide Stacks guide and our Longevity Peptide Stacks page.
Epithalon (Epitalon)
Mechanism of Action
Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from the pineal gland peptide epithalamin, developed by Professor Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology. Its primary research-relevant mechanisms include:
- Telomerase activation — Epithalon has been shown to upregulate telomerase activity in human somatic cells, as measured by TRAP (telomeric repeat amplification protocol) assays. Increased telomerase activity may counteract telomere shortening, one of the fundamental hallmarks of aging.
- Melatonin modulation — Through its pineal gland origin, epithalon has been studied for its ability to normalize melatonin secretion patterns in aging animal models, with implications for circadian rhythm restoration.
- Antioxidant activity — Epithalon has demonstrated reactive oxygen species (ROS) scavenging properties and upregulation of endogenous antioxidant enzymes, reducing oxidative damage to cellular macromolecules.
- Gene expression regulation — Research suggests epithalon influences the expression of genes involved in aging, including those governing cell cycle regulation and DNA repair pathways.
Preclinical Research Highlights
- Telomere lengthening: Studies in human lymphocyte and fibroblast cultures demonstrated that epithalon treatment increased telomerase activity and produced measurable telomere elongation compared to controls (Khavinson et al., 2004).
- Lifespan extension: Administration of epithalon to aged rats was associated with a statistically significant increase in mean lifespan, concurrent with telomerase activation in hepatic and splenic tissues.
- Melatonin normalization: In aged rodent models, epithalon restored nocturnal melatonin peaks toward youthful levels, suggesting potential circadian rhythm restoration.
- Oxidative stress reduction: Epithalon decreased lipid peroxidation markers and increased superoxide dismutase (SOD) activity in multiple tissue types in rodent studies.
Research Considerations
The majority of epithalon research originates from the Khavinson group, and independent replication of key findings — particularly telomere lengthening in human cells — remains limited. Canadian researchers should note that epithalon is a very small tetrapeptide (~390 Da) with implications for bioavailability study design. No completed human clinical trials exist in Western databases. For comprehensive telomere-specific analysis, see our Epithalon Telomere Research guide.
MOTS-c
Mechanism of Action
MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide encoded by the mitochondrial 12S rRNA gene — making it distinct from nuclear-encoded peptides. Its research-relevant mechanisms include:
- AMPK activation — MOTS-c activates the AMP-activated protein kinase (AMPK) pathway, a central regulator of cellular energy homeostasis and metabolic adaptation, improving insulin sensitivity and glucose uptake in research models.
- Mitochondrial function enhancement — As a mitochondria-derived peptide, MOTS-c directly modulates mitochondrial respiration, fatty acid oxidation, and oxidative phosphorylation efficiency.
- Nuclear-mitochondrial communication — MOTS-c translocates from mitochondria to the nucleus under metabolic stress, regulating adaptive gene expression programs including the integrated stress response.
- Insulin sensitivity modulation — In skeletal muscle models, MOTS-c increases glucose uptake and enhances insulin-mediated signaling cascades, making it relevant to metabolic aging research.
Preclinical Research Highlights
- Metabolic regulation: MOTS-c administration in high-fat diet-fed mice improved glucose tolerance, reduced weight gain, and enhanced exercise capacity (Lee et al., 2015, Cell Metabolism).
- Exercise mimetic properties: MOTS-c enhanced physical performance in aged mice, increasing running distance and endurance, with corresponding upregulation of oxidative metabolism genes.
- Age-related decline: Circulating MOTS-c levels decline with age in humans, and MOTS-c supplementation in aged mice improved multiple metabolic parameters, suggesting a role in age-associated metabolic dysfunction.
- Osteoporosis prevention: Research models demonstrated that MOTS-c promotes osteoblast differentiation and reduces osteoclast activity, suggesting potential applications in bone density research.
Research Considerations
MOTS-c research is comparatively recent (first characterized in 2015), and the body of literature, while growing rapidly, is smaller than that for more established peptides. Most studies use parenteral administration in rodent models, and translational data in humans remains sparse. Canadian labs should consider that as a mitochondrial-encoded peptide, MOTS-c may interact with cellular energy metabolism in ways that require careful dosing and timing controls.
DSIP (Delta Sleep Inducing Peptide)
Mechanism of Action
DSIP (Delta Sleep Inducing Peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit hypothalamic tissue in the 1970s. While initially characterized for its sleep-promoting effects, DSIP has since been recognized as a multifunctional neuropeptide with longevity-relevant mechanisms:
- Delta sleep enhancement — DSIP increases the proportion of slow-wave (delta) sleep, the deep restorative sleep phase during which growth hormone secretion, tissue repair, and memory consolidation are maximized. Declining delta sleep is a hallmark of aging.
- HPA axis modulation — DSIP has been shown to normalize hypothalamic-pituitary-adrenal (HPA) axis function, reducing elevated cortisol levels and normalizing circadian cortisol rhythms in research models.
- Antioxidant and neuroprotective activity — DSIP reduces lipid peroxidation and upregulates endogenous antioxidant defenses, particularly in brain tissue. It has demonstrated neuroprotective effects in ischemia-reperfusion models.
- Thermoregulation and stress adaptation — DSIP modulates core body temperature regulation and improves stress tolerance, both of which are relevant to age-related physiological decline.
Preclinical Research Highlights
- Sleep architecture restoration: In rodent models, DSIP administration increased delta sleep duration and improved sleep continuity, particularly in aged subjects with fragmented sleep patterns.
- Cortisol normalization: Studies in chronically stressed animal models demonstrated that DSIP reduced cortisol levels and restored normal circadian cortisol patterns.
- Neuroprotection: DSIP showed neuroprotective effects in cerebral ischemia models, reducing infarct volume and improving neurological outcome scores.
- Pain modulation: DSIP demonstrated analgesic properties in chronic pain models, interacting with endogenous opioid systems without producing dependence.
Research Considerations
DSIP has a paradoxical pharmacokinetic profile — it appears to cross the blood-brain barrier despite its peptide nature, though the mechanism remains debated. Much of the foundational DSIP research was conducted in the 1970s–1990s, and modern replication with current methodologies is needed. Canadian researchers should note that DSIP’s effects are highly dose-dependent and may follow a U-shaped dose-response curve. For deeper analysis, see our DSIP Research Guide and DSIP Sleep & Cognitive Research page.
NAD+ (Nicotinamide Adenine Dinucleotide)
Mechanism of Action
NAD+ is not a peptide but a dinucleotide coenzyme essential for all living cells. It serves as a critical electron carrier in redox reactions and a required substrate for several classes of longevity-relevant enzymes:
- Sirtuin activation — NAD+ is an obligate co-substrate for the sirtuin family of deacetylases (SIRT1–7), which regulate mitochondrial biogenesis, DNA repair, inflammation, and metabolic homeostasis. Declining NAD+ levels directly impair sirtuin activity with age.
- PARP-mediated DNA repair — Poly(ADP-ribose) polymerases (PARPs) consume NAD+ to execute DNA damage repair. Excessive PARP activation in aging cells further depletes NAD+, creating a vicious cycle of genomic instability.
- CD38 degradation — The age-related increase in CD38 (a NAD+-consuming ectoenzyme on inflammatory cells) is a major driver of NAD+ decline, representing both a biomarker and therapeutic target.
- Cellular energy metabolism — NAD+ is indispensable for glycolysis, the TCA cycle, and oxidative phosphorylation. Age-related NAD+ depletion directly impairs mitochondrial ATP production and cellular energetics.
Preclinical Research Highlights
- NAD+ decline with age: Multiple studies have confirmed that NAD+ levels decline 50% or more between youth and old age in human tissues, with corresponding declines in sirtuin activity and mitochondrial function (Massudi et al., 2012).
- Metabolic improvement: NAD+ supplementation in aged mice improved insulin sensitivity, exercise capacity, and mitochondrial respiration in skeletal muscle (Zhang et al., 2016).
- Neuroprotection: NAD+ administration in neurodegenerative disease models demonstrated reduced neuronal death and improved cognitive function, mediated through SIRT1-dependent pathways.
- Cardiovascular protection: In aged mouse models, NAD+ supplementation reversed vascular endothelial dysfunction and improved arterial stiffness, restoring vascular function to youthful levels.
Research Considerations
While NAD+ supplementation shows promise in preclinical models, the optimal delivery method (intravenous vs. intraperitoneal vs. oral precursors) remains an active area of investigation. Direct NAD+ supplementation faces bioavailability challenges that have led many researchers to study NAD+ precursors (NMN, NR) as alternatives. Canadian labs should note that NAD+ is a large, charged molecule (663 Da) with specific handling and storage requirements. For a comprehensive NAD+ research overview, see our NAD+ Research Guide.
Thymosin Alpha-1 (Tα1)
Mechanism of Action
Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue. While its primary characterization is as an immunomodulatory peptide, its relevance to longevity research stems from the critical role immune surveillance plays in aging (immunosenescence):
- T-cell maturation and activation — Tα1 promotes differentiation of T-cell precursors in the thymus and enhances Th1 cytokine responses (IFN-γ, IL-2), counteracting the age-related shift toward Th2 dominance.
- Dendritic cell activation — Tα1 upregulates MHC class II expression and co-stimulatory molecules (CD80, CD86) on dendritic cells, enhancing antigen presentation capacity that declines with age.
- NK cell augmentation — Tα1 enhances natural killer cell cytotoxic activity, which is crucial for immune surveillance against virally infected and transformed cells.
- TLR signaling — Tα1 interacts with TLR2 and TLR9, providing innate immune activation relevant to both anti-infective and anti-tumour research.
- Anti-inflammatory regulation — Paradoxically, Tα1 can also modulate excessive inflammatory responses by reducing pro-inflammatory cytokine storms while maintaining effective pathogen clearance — a balance often disrupted in aging.
Preclinical and Clinical Research Highlights
- Immunosenescence counteraction: In aged rodent models, Tα1 restored T-cell proliferative responses and NK cell activity toward youthful levels, suggesting relevance to age-associated immune decline.
- Infection resistance: Tα1 reduced mortality in rodent sepsis models through cytokine normalization (Romani et al., 2012).
- Oncology adjuvant: Combination studies with checkpoint inhibitors showed Tα1 may enhance anti-tumour T-cell responses in murine solid tumour models.
- Clinical approval (thymalfasin): Tα1 is approved in over 35 countries as Zadaxin for hepatitis B and C, supporting its translational profile — one of the few peptides in this guide with extensive human clinical data.
Research Considerations
Thymosin Alpha-1 has the strongest clinical evidence base of any compound in this guide, with completed human trials in infectious disease and oncology. For longevity research, the key question is whether Tα1’s immunomodulatory properties can meaningfully counteract immunosenescence — the progressive decline in immune function that accompanies aging. Canadian labs should note that Tα1 is structurally and functionally distinct from Thymosin Beta-4 (TB-500). For comprehensive immune modulation research context, see our Thymosin Alpha-1 Guide.
Sourcing Longevity Peptides in Canada
All five compounds covered in this guide are available through Webber Science for Canadian research institutions and independent laboratories. Webber ships domestically with standard cold-pack fulfillment and provides product documentation including CoA (certificate of analysis) data on request.
For information on combining these peptides in research protocols, see our Longevity Peptide Stacks guide. For additional research context, browse the Webber Peptide Library or use the Research Calculator for reconstitution and dosing reference.